Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.

"appendix a supplementary material the following are the supplementary data to this article: supplementary data 1 data availability data will be made available on request."

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors are employees and shareholders of Novavax, Inc."

"Funding This work was funded by Novavax, Inc., and the sponsor had primary responsibility for study design, study vaccines, protocol development, study monitoring, data management, and statistical analyses. This manuscript summarizes four randomized placebo-controlled trials. The phase 1/2 2019nCoV-101 study (NCT04368988) was supported by the Coalition for Epidemic Preparedness Innovations. The phase 3 2019nCoV-301 study (NCT04611802) was supported by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The phase 3 2019nCoV-302 study (EudraCT number, 2020-004123-16) was supported by Novavax, Inc. The phase 2A/2B 2019nCoV-501 study (NCT04533399) was supported by Novavax, Inc. and the Bill and Melinda Gates Foundation."